118292-41-4

Usage

Uses

Used in Pharmaceutical Industry:
AGN 190299 is used as an active metabolite for its role in the treatment of various skin conditions, such as acne and psoriasis. As the principal active metabolite of Tazarotene, it exhibits potent effects on the regulation of cell differentiation and proliferation, making it a valuable compound in the development of therapeutic agents for skin-related disorders.
Used in Research and Development:
In the field of research and development, AGN 190299 is utilized as a key compound for studying the mechanisms of action and potential applications of Tazarotene and its derivatives. Its unique chemical structure allows scientists to explore new avenues in drug discovery and development, particularly in the areas of dermatology and other related medical fields.
Used in Cosmetic Industry:
AGN 190299 is also employed as an active ingredient in the cosmetic industry, where it is used for its potential benefits in improving skin health and appearance. Its role in regulating cell differentiation and proliferation can contribute to the development of anti-aging and skin rejuvenation products, offering consumers effective solutions for maintaining healthy and youthful skin.

InChI:InChI=1/C19H17NO2S/c1-19(2)9-10-23-17-8-4-13(11-16(17)19)3-6-15-7-5-14(12-20-15)18(21)22/h4-5,7-8,11-12H,9-10H2,1-2H3,(H,21,22)

Upstream product

• 118292-40-3 tazarotene 
• 952294-17-6 6-[2-(4,4-Dimethylthiochroman-6-yl)ethynyl]nicotinonitrile 

Downstream Products

• 118292-40-3 tazarotene 

Relevant academic research and scientific papers

NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROLASE

The present disclosure is generally directed to compositions and methods for treating diseases that are ameliorated by the inhibition of CYP26 mediated retinoic acid metabolism.

Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene

The present invention provides a novel intermediate of ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate or a pharmaceutically acceptable salt thereof and a process for its preparation. The present invention also provides for the preparation of ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate of Formula I or a pharmaceutically acceptable salt thereof using the intermediate.

Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity

Retinoid-like activity is exhibited by compounds of the formula STR1 where X is S, O, or NR' where R' is hydrogen or lower alkyl; R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-4; and B is H, --COOH or a pharmaceutically acceptable salt, ester or amide thereof, --CH2 OH or an ether or ester derivative, or --CHO or an acetal derivative, or --COR1 or a ketal derivative where R1 is --(CH2)m CH3 where m is 0-4, or a pharmaceutically acceptable salt thereof.

Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity

Retinoid-like activity is exhibited by compounds of the formula STR1 where X is S, O, or NR' where R' is hydrogen or lower alkyl; R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-2; and B is H, --COOH or a pharmaceutically acceptable salt, ester or amide thereof, --CH2 OH or an ether or ester derivative, or --CHO or an acetal derivative, or --COR1 or a ketal derivative where R1 is --(CH2)m CH3 where m is 0-4, or a pharmaceutically acceptable salt thereof.